Shows NIR-activated nanozymes improve cartilage and bone health in osteoarthritis, suggesting a novel treatment approach.
Osteoarthritis (OA) is a progressive whole-joint disorder involving cartilage degeneration, oxidative stress, synovial inflammation, and subchondral bone remodeling. Current treatments mainly provide symptomatic relief and rarely restore joint microenvironmental homeostasis. Here, we developed a multifunctional near-infrared (NIR)-responsive CuTA@PDA@PTH nanozyme, termed CPP, for OA therapy. CPP was constructed through copper–tannic acid coordination, polydopamine coating, and PTH 1–34 incorporation, integrating antioxidant catalytic activity, photothermal responsiveness, and peptide-mediated bioactivity. CPP exhibited uniform morphology, good dispersibility, stable photothermal behavior, and broad-spectrum ROS-scavenging activity with SOD-like and CAT-like functions. In vitro, NIR-activated CPP reduced H₂O₂-induced ROS accumulation, lipid peroxidation, mitochondrial dysfunction, and apoptosis in chondrocytes, while promoting proliferation and restoring cartilage matrix homeostasis. CPP-NIR also downregulated inflammatory and catabolic markers, attenuated M1-associated activation, favored an anti-inflammatory M2-like phenotype, and enhanced BMSC migration and osteogenic differentiation under oxidative stress. In a DMM-induced mouse OA model, intra-articular CPP combined with NIR irradiation prolonged joint retention, attenuated cartilage degeneration, reduced osteophyte formation, improved subchondral bone microarchitecture, and alleviated synovial inflammation. These findings support NIR-activated CPP as a multi-axis nanozyme platform for redox, immune, cartilage, and subchondral bone microenvironment regulation in OA.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: